Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B

Catalog No. B256088
Click to view available options
Quantity:
30 Tests

Rapidly detect and differentiation between SARS-CoV-2, Flu A, and Flu B from one sample on one assay in 15 minutes with the newest BD Veritor assay.

  • Detect and differentiate between SARS-CoV-2, Flu A, and Flu B from one sample on one assay in just 15 minutes
  • Identical workflow to the SARS-CoV-2 assay Dual anterior nares sample collection. Clear, digitally displayed results that detect positives not recognized by the unaided eye
  • Requires BD Veritor Plus Analyzers running firmware v5.50 or higher
  • Check out seasonal promotions for offers that include free analyzers with the purchase of kits.
TRUSTED_SUSTAINABILITY

Specifications

Certifications/Compliance Certificate of Conformance
Content And Storage 2°C to 30°C
Control Sets SARS+, Flu A+, Flu B+ included
CPT Code 87428
CE Marker No
Clia Complexity Waived
Detectable Analytes SARS-CoV-2, Influenza A/B
DoA Calibrators No
Sample Type Dual Anterior Nares
Sensitivity 86.7% (SARS-CoV-2)
Type Rapid Antigen
For Use With (Application) Lateral Flow Immunoassay
For Use With (Equipment) BD Veritor Plus Analyzer (256066)
Quantity 30 Tests
Specificity 0.995
Test Time 15 min.
Form Liquid
Show More Show Less

*The BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for the in vitro, simultaneous qualitative detection and differentiation of SARS-CoV-2 nucleocapsid antigen and/or influenza A and B nucleoprotein antigens directly from anterior nasal swab samples taken from individuals who are suspected of a viral respiratory infection consistent with COVID-19 by a healthcare provider, within the first six days of symptom onset.

  • This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories.
  • This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens.
  • The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.